Particularly, D3R has emerged as a potential target for the treatment of PD due to their pharmacological similarity to the D2R, but without their added risk for the side-effects likely associated with the peripherally distributed D2Rs [5,6,13]. The gene discussed is DRD2; the disease is Parkinson disease.